Literature DB >> 23727344

Cognitive reserve and symptom experience in multiple sclerosis: a buffer to disability progression over time?

Carolyn E Schwartz1, Brian R Quaranto, Brian C Healy, Ralph H Benedict, Timothy L Vollmer.   

Abstract

OBJECTIVE: To investigate the possible buffering effect of cognitive reserve on symptom experience for multiple sclerosis (MS) disease course.
DESIGN: Secondary analysis of longitudinal data from the North American Research Committee on MS Registry.
SETTING: Registry study and web-based supplemental survey. PARTICIPANTS: People with MS (N=859).
INTERVENTIONS: Not applicable. MAIN OUTCOME MEASURES: Two health outcome measures, the Symptom Inventory and the Performance Scales, were collected biannually over 1 and 6 years, respectively. Active and passive cognitive reserve was measured using the Stern Leisure Activities and the Sole-Padulles Childhood Enrichment tools, respectively. Linear regression, chi-square, multilevel random-effects modeling, and classification and regression tree modeling were used to compare cross-sectional means, disease course by cognitive reserve, longitudinal trajectories, and active cognitive reserve item endorsement by disability groups, respectively.
RESULTS: Patients with high-active reserve had a lesser symptom burden than those with low-active reserve independent of passive reserve (P<.01). Cognitive reserve was associated with course of disease, such that high-active patients were overrepresented among relapsing-remitting patients, and underrepresented among patients with progressive disease (χ(2)=14.7, P<.03). Longitudinal modeling revealed a significant interaction of active reserve and time in mobility, fatigue, and overall disability in the whole sample (P<.05 in all comparisons). Among patients whose disability trajectories changed over time, active cognitive reserve was associated with less deterioration (P<.001). Passive cognitive reserve evidenced no effect in the longitudinal analyses. Active cognitive reserve scores across disability groups had a similar range but comprised different items, indicating that patients maintain active cognitive reserve with different activities as the disease progresses.
CONCLUSIONS: Our findings suggest that active cognitive reserve is a buffer for functional limitation across disability groupings. Cognitive reserve may provide an alternative lens for thinking about the disease course of MS, providing a longer "runway" until disability accrual through cortical remodeling. Loss of cognitive reserve may explain the onset of progressive disease in MS.
Copyright © 2013 American Congress of Rehabilitation Medicine. Published by Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Cognitive reserve; Course of disease; MRI; MS; Multiple sclerosis; NARCOMS; Natural history; North American Research Committee on Multiple Sclerosis; PPMS; People with disabilities; RRMS; Rehabilitation; SPMS; Secondary progressive multiple sclerosis; Symptoms; magnetic resonance imaging; multiple sclerosis; primary progressive multiple sclerosis; relapsing-remitting multiple sclerosis; secondary progressive multiple sclerosis

Mesh:

Year:  2013        PMID: 23727344     DOI: 10.1016/j.apmr.2013.05.009

Source DB:  PubMed          Journal:  Arch Phys Med Rehabil        ISSN: 0003-9993            Impact factor:   3.966


  17 in total

1.  Understanding social forces involved in diabetes outcomes: a systems science approach to quality-of-life research.

Authors:  David W Lounsbury; Gary B Hirsch; Chawntel Vega; Carolyn E Schwartz
Journal:  Qual Life Res       Date:  2013-09-24       Impact factor: 4.147

2.  A new perspective on proxy report: Investigating implicit processes of understanding through patient-proxy congruence.

Authors:  Carolyn E Schwartz; Armon Ayandeh; Jonathan D Rodgers; Paul Duberstein; Bianca Weinstock-Guttman; Ralph H B Benedict
Journal:  Qual Life Res       Date:  2015-06-03       Impact factor: 4.147

3.  Assessing reserve-building pursuits and person characteristics: psychometric validation of the Reserve-Building Measure.

Authors:  Carolyn E Schwartz; Wesley Michael; Jie Zhang; Bruce D Rapkin; Mirjam A G Sprangers
Journal:  Qual Life Res       Date:  2017-09-06       Impact factor: 4.147

4.  Telemedicine for Monitoring MS Activity and Progression.

Authors:  Nuria Sola-Valls; Yolanda Blanco; Maria Sepúlveda; Eugenia Martinez-Hernandez; Albert Saiz
Journal:  Curr Treat Options Neurol       Date:  2015-11       Impact factor: 3.598

Review 5.  Patient healthcare trajectory. An essential monitoring tool: a systematic review.

Authors:  Jessica Pinaire; Jérôme Azé; Sandra Bringay; Paul Landais
Journal:  Health Inf Sci Syst       Date:  2017-04-12

6.  Reserve-building activities in multiple sclerosis patients and healthy controls: a descriptive study.

Authors:  Carolyn E Schwartz; Armon Ayandeh; Murali Ramanathan; Ralph Benedict; Michael G Dwyer; Bianca Weinstock-Guttman; Robert Zivadinov
Journal:  BMC Neurol       Date:  2015-08-12       Impact factor: 2.474

7.  The relationship between the rate of brain volume loss during first 24 months and disability progression over 24 and 48 months in relapsing MS.

Authors:  Douglas R Jeffery; Elisabetta Verdun Di Cantogno; Shannon Ritter; Daniela Piani Meier; Ernst-Wilhelm Radue; William Camu
Journal:  J Neurol       Date:  2015-11-14       Impact factor: 4.849

Review 8.  Measurement and maintenance of reserve in multiple sclerosis.

Authors:  Brian M Sandroff; Carolyn E Schwartz; John DeLuca
Journal:  J Neurol       Date:  2016-04-12       Impact factor: 4.849

9.  Resilience to health challenges is related to different ways of thinking: mediators of physical and emotional quality of life in a heterogeneous rare-disease cohort.

Authors:  Carolyn E Schwartz; Wesley Michael; Bruce D Rapkin
Journal:  Qual Life Res       Date:  2017-06-28       Impact factor: 4.147

10.  Reserve-related activities and MRI metrics in multiple sclerosis patients and healthy controls: an observational study.

Authors:  Carolyn E Schwartz; Michael G Dwyer; Ralph Benedict; Bianca Weinstock-Guttman; Niels P Bergsland; Jei Li; Murali Ramanathan; Robert Zivadinov
Journal:  BMC Neurol       Date:  2016-07-19       Impact factor: 2.474

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.